General Proximity Secures Investment from FreeMind and Daewoong for Next-Generation Induced Proximity Platform
核心洞察
General Proximity (搜索), a San Francisco biotech company, received investment from FreeMind Investments (搜索) and Daewoong Pharmaceutical (搜索) for its innovative induced proximity medicine platform.
The company's proprietary OmniTAC (搜索) platform scans the "effectome" to identify effector proteins (搜索) that can modulate previously undruggable disease-causing targets.
General Proximity (搜索) has secured over $20 million in funding, five "Golden Ticket" awards from major pharma companies, and a strategic collaboration with Daiichi Sankyo.
FreeMind Investments (搜索) (FMI), a venture capital fund launched in partnership between FreeMind Group and Daewoong Pharmaceutical (搜索) Co., Ltd., announced its investment in General Proximity (搜索), a San Francisco-based biotechnology company pioneering next-generation induced proximity medicines. The investment reflects General Proximity's strong scientific position and innovation in the emerging field of induced proximity therapeutics, along with Daewoong Pharmaceutical's interest in potential future strategic collaboration.
Revolutionary Platform Technology
General Proximity (搜索) has developed what the company describes as the first mechanism-agnostic proximity discovery engine centered on scanning the "effectome"—the set of effector proteins (搜索) that can modulate disease-causing proteins (搜索) to control biology. This approach enables the development of highly efficacious proximity therapeutics for targets previously considered beyond the reach of medicine.
The company's proprietary OmniTAC (搜索) platform represents a significant advancement in the field, allowing for unbiased identification of effector proteins (搜索) capable of modulating disease-relevant targets. This technology unlocks new therapeutic opportunities across multiple disease areas, including oncology (搜索), cardiometabolic disease (搜索), neurodegeneration (搜索), and longevity.
Strong Industry Validation
General Proximity (搜索) has demonstrated significant traction in the pharmaceutical industry, having raised over $20 million in funding to date. The company has secured five "Golden Ticket" awards from major pharmaceutical companies, including AbbVie (搜索), Servier, Astellas, Ono (搜索), and Bristol-Myers Squibb. Additionally, the company has received non-dilutive grants from ARPA-H and the NIH's National Cancer (搜索) Institute.
Most recently, General Proximity (搜索) announced a strategic multi-target collaboration with Daiichi Sankyo, applying its proprietary OmniTAC (搜索) platform to several oncology (搜索) programs. This collaboration validates the platform's potential for addressing challenging targets in cancer (搜索) therapeutics.
Strategic Investment Partnership
The investment comes from FreeMind Investments (搜索), which leverages a unique approach to venture capital by using non-dilutive funding review processes as a differentiated due diligence tool. FreeMind Group, founded in 1999, has secured over $2 billion for its life science clients and currently garners over $100 million annually across various funding sources including NIH, DoD, BARDA, NSF, FDA, and private foundations.
Daewoong Pharmaceutical (搜索), established in 1945, is a leading South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals globally. The company maintains strategic partnerships in more than 100 countries worldwide and brings significant expertise in drug development and commercialization to the partnership.
Leadership Perspectives
"FMI was built to translate deep non-dilutive funding intelligence into investment conviction," said Ram May-Ron, Founder and Managing Partner at FreeMind Investments (搜索). "General Proximity (搜索) stands out for the quality of its science, the strength of its team, and its potential to unlock new therapeutic options for targets long considered out of reach."
Seongsoo Park, CEO of Daewoong Pharmaceutical (搜索) Co., Ltd., emphasized the strategic value of the partnership: "We see significant strategic potential in General Proximity (搜索)'s induced proximity approach. We look forward to building a future strategic collaboration with the General Proximity team."
Armand Cognetta, Founder & Chief Executive Officer of General Proximity (搜索), expressed enthusiasm about the new partnership: "We are excited to welcome FreeMind Investments (搜索) and Daewoong Pharmaceutical (搜索) as investors. Their investment conviction and deep expertise in drug discovery validates our scientific approach and the high-impact pipeline we are building."
Advancing Multiple Therapeutic Programs
General Proximity (搜索) is currently advancing multiple preclinical programs generated by its OmniTAC (搜索) platform across various therapeutic areas. The company's focus on oncology (搜索), cardiometabolic disease (搜索), neurodegeneration (搜索), and longevity represents a broad approach to addressing unmet medical needs through its innovative proximity medicine technology.
The investment provides General Proximity (搜索) with additional resources to advance its pipeline while potentially opening doors to co-development opportunities and entry into Asian markets through the partnership with Daewoong Pharmaceutical (搜索).